AbbVie announced Phase 2 results showing adults with moderate to severe hidradenitis suppurativa who had previously failed anti-TNF therapy who received lutikizumab 300 mg every other week or 300 mg weekly achieved higher response rates than placebo in the primary endpoint of achieving HS Clinical Response at week 16. Based on these data, AbbVie will advance its clinical program of lutikizumab in HS to Phase 3. Lutikizumab is AbbVie’s investigational, dual-variable-domain interleukin 1alpha/1beta antagonist. Studies have shown IL 1alpha and 1beta are elevated in HS lesions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABBV:
- AbbVie and Umoja Biopharma partnering to develop in-situ CAR-T cell therapies
- CVS Caremark accelerates biosimilars adoption through formulary changes
- AbbVie Stock (NASDAQ:ABBV): Goodbye Wrinkles, Hello Profits
- AbbVie price target lowered to $180 from $195 at Wells Fargo
- Cerevel Therapeutics price target raised to $45 from $25 at JPMorgan